CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Revance The - RVNC CFD

    7.19
    6.84%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.06
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026235 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026235%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004012 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004012%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Revance Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 6.73
    Open* 6.53
    1-Year Change* -69.77%
    Day's Range* 6.53 - 7.19
    52 wk Range 5.72-37.98
    Average Volume (10 days) 2.46M
    Average Volume (3 months) 44.85M
    Market Cap 634.89M
    P/E Ratio -100.00K
    Shares Outstanding 87.81M
    Revenue 214.16M
    EPS -4.99
    Dividend (Yield %) N/A
    Beta 0.86
    Next Earnings Date N/A

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 1, 2023 7.19 0.46 6.84% 6.73 7.19 6.43
    Nov 30, 2023 6.73 -0.20 -2.89% 6.93 7.06 6.71
    Nov 29, 2023 6.90 -0.17 -2.40% 7.07 7.50 6.89
    Nov 28, 2023 7.02 0.27 4.00% 6.75 7.15 6.62
    Nov 27, 2023 6.88 -0.25 -3.51% 7.13 7.13 6.74
    Nov 24, 2023 7.18 0.00 0.00% 7.18 7.55 7.13
    Nov 22, 2023 7.26 -0.07 -0.95% 7.33 7.35 7.08
    Nov 21, 2023 7.20 -0.05 -0.69% 7.25 7.35 7.00
    Nov 20, 2023 7.43 0.07 0.95% 7.36 7.51 7.04
    Nov 17, 2023 7.25 0.35 5.07% 6.90 7.59 6.82
    Nov 16, 2023 6.90 0.11 1.62% 6.79 7.13 6.40
    Nov 15, 2023 6.98 0.22 3.25% 6.76 7.54 6.74
    Nov 14, 2023 6.72 0.51 8.21% 6.21 6.72 6.21
    Nov 13, 2023 5.78 -0.12 -2.03% 5.90 6.07 5.69
    Nov 10, 2023 5.94 -0.87 -12.78% 6.81 6.81 5.76
    Nov 9, 2023 6.87 -0.45 -6.15% 7.32 8.40 6.80
    Nov 8, 2023 8.29 -0.19 -2.24% 8.48 8.56 8.09
    Nov 7, 2023 8.54 -0.47 -5.22% 9.01 9.05 8.52
    Nov 6, 2023 9.05 -0.25 -2.69% 9.30 9.32 9.00
    Nov 3, 2023 9.20 0.36 4.07% 8.84 9.23 8.74

    Revance The Events

    Time (UTC) Country Event
    No events scheduled
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 132.565 77.798 15.325 0.413 3.729
    Revenue 132.565 77.798 15.325 0.413 3.729
    Total Operating Expense 474.523 352.474 288.487 164.872 146.363
    Selling/General/Admin. Expenses, Total 217.121 192.094 149.743 62.011 53.863
    Research & Development 99.639 114.484 123.724 102.861 92.5
    Unusual Expense (Income) 69.789 0 0
    Operating Income -341.958 -274.676 -273.162 -164.459 -142.634
    Interest Income (Expense), Net Non-Operating -11.583 -5.875 -10.955 5.333 3.839
    Other, Net -2.181 -0.759 -0.592 -0.303 -0.773
    Net Income Before Taxes -355.722 -281.31 -284.709 -159.429 -139.568
    Net Income After Taxes -356.422 -281.31 -282.089 -159.429 -142.568
    Net Income Before Extra. Items -356.422 -281.31 -282.089 -159.429 -142.568
    Net Income -356.422 -281.31 -282.089 -159.429 -142.568
    Income Available to Common Excl. Extra. Items -356.422 -281.31 -282.089 -159.429 -142.568
    Income Available to Common Incl. Extra. Items -356.422 -281.31 -282.089 -159.429 -142.568
    Diluted Net Income -356.422 -281.31 -282.089 -159.429 -142.568
    Diluted Weighted Average Shares 72.7133 67.5078 58.0092 43.4608 36.1716
    Diluted EPS Excluding Extraordinary Items -4.90174 -4.16707 -4.86284 -3.66834 -3.94144
    Diluted Normalized EPS -4.27788 -4.16707 -4.86284 -3.66834 -3.94144
    Total Extraordinary Items 0
    Cost of Revenue, Total 51.667 23.41 4.769
    Gross Profit 80.898 54.388 10.556
    Depreciation / Amortization 36.307 22.486 10.251
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 58.134 49.331 49.921 29.015 28.368
    Revenue 58.134 49.331 49.921 29.015 28.368
    Cost of Revenue, Total 21.307 16.171 23.515 10.736 9.523
    Gross Profit 36.827 33.16 26.406 18.279 18.845
    Total Operating Expense 123.633 107.363 194.332 106.499 86.21
    Selling/General/Admin. Expenses, Total 76.344 63.869 63.545 64.093 46.186
    Research & Development 22.452 20.704 19.541 26.103 24.913
    Depreciation / Amortization 3.53 6.619 17.942 5.567 5.588
    Operating Income -65.499 -58.032 -144.411 -77.484 -57.842
    Interest Income (Expense), Net Non-Operating -1.22 -1.527 0.259 -6.627 -3.316
    Other, Net -0.599 -0.234 -1.8 0.118 -0.277
    Net Income Before Taxes -67.318 -59.793 -145.952 -83.993 -61.435
    Net Income After Taxes -67.318 -59.793 -145.952 -84.693 -61.435
    Net Income Before Extra. Items -67.318 -59.793 -145.952 -84.693 -61.435
    Net Income -67.318 -59.793 -145.952 -84.693 -61.435
    Income Available to Common Excl. Extra. Items -67.318 -59.793 -145.952 -84.693 -61.435
    Income Available to Common Incl. Extra. Items -67.318 -59.793 -145.952 -84.693 -61.435
    Diluted Net Income -67.318 -59.793 -145.952 -84.693 -61.435
    Diluted Weighted Average Shares 83.6859 81.1341 80.2079 72.2083 70.0615
    Diluted EPS Excluding Extraordinary Items -0.80441 -0.73696 -1.81967 -1.1729 -0.87687
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.80441 -0.73696 -0.94957 -1.1729 -0.87687
    Unusual Expense (Income) 69.789
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 374.727 246.117 450.003 296.602 207.922
    Cash and Short Term Investments 340.707 225.071 436.505 290.115 175.812
    Cash & Equivalents 108.965 110.623 333.558 171.16 73.256
    Short Term Investments 231.742 114.448 102.947 118.955 102.556
    Total Receivables, Net 11.339 3.348 1.829 0 27
    Accounts Receivable - Trade, Net 11.339 3.348 1.829 0 27
    Prepaid Expenses 4.356 7.544 5.793 6.487 5.11
    Other Current Assets, Total
    Total Assets 581.9 531.163 720.22 340.287 226.348
    Property/Plant/Equipment, Total - Net 67.755 69.001 47.131 41.286 14.449
    Property/Plant/Equipment, Total - Gross 96.347 92.33 66.622 58.152 28.421
    Accumulated Depreciation, Total -28.592 -23.329 -19.491 -16.866 -13.972
    Long Term Investments
    Other Long Term Assets, Total 35.239 13.747 4.779 2.399 3.977
    Total Current Liabilities 75.682 67.289 60.964 40.979 31.97
    Accounts Payable 4.546 10.603 12.657 8.01 8.434
    Accrued Expenses 57.037 42.862 35.903 21.9 14.407
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0.669 0
    Other Current Liabilities, Total 13.43 13.824 12.404 11.069 9.129
    Total Liabilities 569.3 462.692 345.93 114.797 80.726
    Total Long Term Debt 379.374 280.635 180.526 0 0
    Long Term Debt 379.374 280.635 180.526
    Other Liabilities, Total 114.244 114.768 104.44 73.818 48.756
    Total Equity 12.6 68.471 374.29 225.49 145.622
    Common Stock 0.082 0.072 0.069 0.052 0.037
    Additional Paid-In Capital 1767.27 1466.37 1500.51 1069.64 830.368
    Retained Earnings (Accumulated Deficit) -1754.37 -1397.95 -1126.29 -844.204 -684.775
    Other Equity, Total -0.374 -0.018 0 0.003 -0.008
    Total Liabilities & Shareholders’ Equity 581.9 531.163 720.22 340.287 226.348
    Total Common Shares Outstanding 82.3858 71.5841 69.1787 52.3747 36.9752
    Preferred Stock - Non Redeemable, Net 0 0 0 0
    Total Inventory 18.325 10.154 5.876
    Goodwill, Net 77.175 146.964 146.964
    Intangibles, Net 27.004 55.334 71.343
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 388.519 378.947 323.024 374.727 415.594
    Cash and Short Term Investments 300.245 319.723 273.949 340.707 378.627
    Cash & Equivalents 179.319 141.235 136.678 108.965 104.491
    Short Term Investments 120.926 178.488 137.271 231.742 274.136
    Total Receivables, Net 25.414 17.043 15.373 11.339 11.732
    Accounts Receivable - Trade, Net 25.414 17.043 15.373 11.339 11.732
    Total Inventory 46.214 34.448 27.775 18.325 17.178
    Prepaid Expenses 16.371 7.458 5.652 4.356 8.057
    Total Assets 532.487 597.535 547.801 581.9 711.591
    Property/Plant/Equipment, Total - Net 95.198 73.588 79.662 67.755 73.22
    Property/Plant/Equipment, Total - Gross 102.951 96.347 100.272
    Accumulated Depreciation, Total -23.289 -28.592 -27.052
    Goodwill, Net 0 77.175 77.175 77.175 146.964
    Intangibles, Net 10.507 28.461 31.223 27.004 42.866
    Other Long Term Assets, Total 38.263 39.364 36.717 35.239 32.947
    Total Current Liabilities 82.158 74.079 77.985 75.682 74.732
    Accounts Payable 4.775 8.345 12.996 4.546 0.744
    Accrued Expenses 57.317 39.481 36.711 57.037 50.395
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 10.206 10.748 9.667 13.43 14.197
    Total Liabilities 638.688 570.749 574.474 569.3 565.878
    Total Long Term Debt 427.101 380.348 379.859 379.374 378.889
    Long Term Debt 427.101 380.348 379.859 379.374 378.889
    Other Liabilities, Total 129.429 116.322 116.63 114.244 112.257
    Total Equity -106.201 26.786 -26.673 12.6 145.713
    Preferred Stock - Non Redeemable, Net 0 0 0 0
    Common Stock 0.088 0.088 0.084 0.082 0.082
    Additional Paid-In Capital 1916.39 1908.24 1787.54 1767.27 1754.51
    Retained Earnings (Accumulated Deficit) -2022.66 -1881.48 -1814.17 -1754.37 -1608.42
    Total Liabilities & Shareholders’ Equity 532.487 597.535 547.801 581.9 711.591
    Total Common Shares Outstanding 87.8133 87.95 84.0172 82.3858 82.2869
    Other Equity, Total -0.013 -0.061 -0.125 -0.374 -0.46
    Current Port. of LT Debt/Capital Leases 9.86 15.505 18.611 0.669 9.396
    Capital Lease Obligations
    Other Current Assets, Total 0.275 0.275 0.275
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -356.422 -281.31 -282.089 -159.429 -142.568
    Cash From Operating Activities -193.548 -221.538 -178.502 -106.161 -104.246
    Cash From Operating Activities 33.732 19.853 10.25 2.909 1.726
    Non-Cash Items 128.477 44.693 56.085 16.087 13.879
    Cash Interest Paid 12.231 5.031 2.53 0 0.016
    Changes in Working Capital 0.665 -4.774 39.972 34.272 22.717
    Cash From Investing Activities -138.798 -29.665 12.131 -17.592 -107.026
    Capital Expenditures -3.21 -10.375 -4.216 -3.238 -6.991
    Other Investing Cash Flow Items, Total -135.588 -19.29 16.347 -14.354 -100.035
    Cash From Financing Activities 331.694 29.869 331.484 221.657 1.782
    Financing Cash Flow Items -8.193 -8.525 -37.666 -2.12 -2.578
    Issuance (Retirement) of Stock, Net 252.834 38.394 90.84 223.777 5.292
    Issuance (Retirement) of Debt, Net 87.053 0 278.31 0 -0.932
    Net Change in Cash -0.652 -221.334 165.113 97.904 -209.49
    Cash Taxes Paid 0.7 0 0.1 3
    Deferred Taxes 0 0 -2.72
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -59.793 -356.422 -210.47 -125.777 -64.342
    Cash From Operating Activities -69.5 -193.548 -163.366 -105.495 -61.27
    Cash From Operating Activities 6.618 33.732 16.266 10.827 5.376
    Non-Cash Items 12.164 128.477 48.354 25.899 14.942
    Changes in Working Capital -28.489 0.665 -17.516 -16.444 -17.246
    Cash From Investing Activities 95.316 -138.798 -179.758 -61.313 44.568
    Capital Expenditures -0.87 -3.21 -1.922 -0.92 -1.456
    Other Investing Cash Flow Items, Total 96.186 -135.588 -177.836 -60.393 46.024
    Cash From Financing Activities 3.265 331.694 337.867 126.478 105.313
    Financing Cash Flow Items -3.73 -8.193 -5.936 -3.853 -1.913
    Issuance (Retirement) of Stock, Net 9.481 252.834 250.653 33.941 9.076
    Issuance (Retirement) of Debt, Net -2.486 87.053 93.15 96.39 98.15
    Net Change in Cash 29.081 -0.652 -5.257 -40.33 88.611
    Deferred Taxes 0
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Capital World Investors Investment Advisor 10.8861 9574874 -501227 2023-06-30 LOW
    Teoxane SA Corporation 7.4479 6550800 2105000 2023-10-20 MED
    BlackRock Institutional Trust Company, N.A. Investment Advisor 6.5028 5719557 307575 2023-06-30 LOW
    GIC Private Limited Sovereign Wealth Fund 6.2452 5492965 1316885 2022-12-31 LOW
    Palo Alto Investors LP Hedge Fund 5.9446 5228609 -41600 2023-06-30 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 5.2724 4637379 53031 2023-06-30 LOW
    Polar Capital LLP Investment Advisor/Hedge Fund 4.7386 4167842 0 2023-06-30 LOW
    Thrivent Asset Management, LLC Investment Advisor 3.692 3247319 1226338 2023-06-30 LOW
    AllianceBernstein L.P. Investment Advisor/Hedge Fund 2.9518 2596263 617706 2023-06-30 LOW
    Franklin Advisers, Inc. Investment Advisor/Hedge Fund 2.5299 2225208 -13555 2023-06-30 LOW
    JP Morgan Asset Management Investment Advisor 2.4739 2175922 -844741 2023-06-30 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 2.3316 2050782 103019 2023-06-30 LOW
    D. E. Shaw & Co., L.P. Hedge Fund 2.2871 2011669 -280242 2023-06-30 MED
    Two Sigma Investments, LP Hedge Fund 2.2066 1940839 -982999 2023-06-30 HIGH
    Fidelity Management & Research Company LLC Investment Advisor 2.1145 1859810 14578 2023-06-30 LOW
    Jennison Associates LLC Investment Advisor/Hedge Fund 2.0911 1839267 205962 2023-06-30 LOW
    Invesco Advisers, Inc. Investment Advisor 1.9854 1746278 1699007 2023-06-30 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.9277 1695510 98996 2023-06-30 LOW
    JPMorgan Asset Management U.K. Limited Investment Advisor/Hedge Fund 1.8898 1662172 -287933 2023-06-30 LOW
    Goldman Sachs & Company, Inc. Research Firm 1.852 1628929 627050 2023-06-30 MED

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Revance The Company profile

    About Revance Therapeutics Inc

    Revance Therapeutics, Inc. is a commercial stage biotechnology company. The Company is focused on advanced aesthetic and therapeutic offerings, including neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a purified botulinum toxin that does not contain human or animal-based components. The Company is also evaluating additional aesthetic and therapeutic indications for DaxibotulinumtoxinA for Injection including the full upper face, which includes glabellar lines, forehead lines and crow’s feet, and adult upper limb spasticity. It offers products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and OPUL. The RHA Collection of dermal fillers is a dermal filler for the correction of dynamic facial wrinkles and folds. OPUL’s product offering includes the point-of-sale platform, software and hardware terminal.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Revance Therapeutics Inc revenues increased from $15.3M to $77.8M. Net loss increased less than 1% to $281.3M. Revenues reflect Product Segment increase from $14.9M to $76.5M, Service Segment increase from $417K to $1.3M. Net loss reflects Research & Development balance decrease of 11% to $99.4M (expense), Interest expense decrease of 59% to $6.3M (expense).

    Industry: Biopharmaceuticals

    1222 Demonbreun Street
    Suite 2000
    NASHVILLE
    TENNESSEE 37203
    US

    Income Statement

    • Annual
    • Quarterly

    News

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    People also watch

    XRP/USD

    0.62 Price
    -0.620% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    Gold

    2,072.25 Price
    +1.760% 1D Chg, %
    Long position overnight fee -0.0193%
    Short position overnight fee 0.0111%
    Overnight fee time 22:00 (UTC)
    Spread 0.30

    US100

    16,001.20 Price
    +0.470% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 7.0

    Oil - Crude

    74.50 Price
    -1.560% 1D Chg, %
    Long position overnight fee -0.0136%
    Short position overnight fee -0.0083%
    Overnight fee time 22:00 (UTC)
    Spread 0.040

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading